Form 4: Bicycle Therapeutics Director Gutierrez-Ramos Reports Stock Option Grant and RSU Award

Director Jose-Carlos Gutierrez-Ramos reports the acquisition of stock options and restricted stock units (RSUs) in Bicycle Therapeutics PLC.

Summary

• Jose-Carlos Gutierrez-Ramos, a director of Bicycle Therapeutics PLC, reported changes in beneficial ownership.
• On January 2, 2025, Gutierrez-Ramos acquired 6,250 ordinary shares through a restricted stock unit (RSU) award and disposed of 23,000 ordinary shares.
• The RSU award vests in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025, and December 15, 2025.
• Each RSU represents a contingent right to receive one ordinary share.
• Gutierrez-Ramos also acquired a stock option to buy 12,500 ordinary shares at an exercise price of $14.
• This option vests in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025, and December 15, 2025, and expires on January 2, 2035.
• Following these transactions, Gutierrez-Ramos directly owns 12,500 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock options and RSU grants, which are standard compensation practices. The disposal of shares is noted but without further context, it's difficult to assess the impact.

Positives

• The acquisition of stock options and RSUs by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 23,000 ordinary shares by the director could be interpreted negatively, although the reason for the disposal is not specified.

Risks

• The vesting of the RSUs and stock options is contingent on continued service, which introduces a risk if the director were to leave the company.
• Market conditions could impact the value of the underlying shares, affecting the value of the RSUs and stock options.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a multi-year commitment from the director.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead, and Biogen also utilize stock options and RSUs as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• The stock option and RSU grants align the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Next Steps

• The director will receive ordinary shares as the RSUs vest on the specified dates.
• The director may exercise the stock options to purchase ordinary shares at $14 per share before the expiration date.

Key Dates